Desentum (private company)

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens from hypersensitivity to tolerance.

We have a unique approach for designing the hypoallergens used in immunotherapy. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of immunotherapeutic products against common types of allergies.

Our goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.

Companies with similar profile to Desentum:

Company	Criteria
BioMensio 45%	Similar verticals: Biotech Similar business models: B2B At least one vc investor: VTT Ventures Minim one investor from outside Scandinavia: Yes
Minima Processor 44%	Similar business models: B2B At least one vc investor: VTT Ventures Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
LymphaTouch 44%	Similar business models: B2B At least one vc investor: ACME Investments Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
Gradientech 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Total raised in a similar range: 5M - 10M USD
Asqella 44%	Similar business models: B2B At least one vc investor: VTT Ventures Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
OxThera 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
Cirqle Biomedical 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
Aiforia 44%	Similar business models: B2B At least one vc investor: ACME Investments, Sto-Rahoitus Oy Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
AFYX Therapeutics 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
STipe Therapeutics 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
NMD Pharma 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
ITBMed 44%	Similar verticals: Biotech, Pharma Similar business models: B2B Minim one investor from outside Scandinavia: Yes
Mobidiag 43%	Similar verticals: Biotech Similar business models: B2B At least one other investor: Springvest Oy Minim one investor from outside Scandinavia: Yes
Biosyntia 43%	Similar verticals: Biotech Similar business models: B2B Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
CysBio 43%	Similar verticals: Biotech Similar business models: B2B Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
Sorbwater Technology 43%	Similar verticals: Biotech Similar business models: B2B Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
Monocl 43%	Similar verticals: Biotech Similar business models: B2B Total raised in a similar range: 5M - 10M USD Minim one investor from outside Scandinavia: Yes
Solar Foods 35%	Similar verticals: Biotech Similar business models: B2B At least one vc investor: VTT Ventures
Quretech Bio 34%	Similar verticals: Biotech, Pharma Similar business models: B2B
Athera 34%	Similar verticals: Biotech, Pharma Similar business models: B2B